Development and validation of a novel clinical decision support tool for sustained remission in Crohn’s disease: a multi-center real-world study

Long-term outcomes for Crohn’s disease (CD) patients treated with infliximab (IFX) remain suboptimal. We developed and validated a clinical decision support tool (CDST) to predict sustained remission in CD patients treated with infliximab (IFX). This multicenter observational study analyzed 746 CD patients across three cohorts. Sustained clinical remission (CREM) was defined as steroid-free Crohn’s Disease Activity Index (CDAI)